by The Middle East and Asia Pacific cell and gene therapy market is poised to experience accelerated growth driven by enhanced regulatory frameworks. Cell and gene therapies have revolutionized the treatment of hard-to-cure, life-threatening diseases like cancer, genetic disorders and chronic illnesses. They work by transferring genetic material or cells into patients’ bodies to treat diseases. This fast-growing market is estimated to be valued at US$ 4147.82 Th in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key drivers of growth in this market is the changing regulatory landscape. Many countries are actively working to establish appropriate regulations that support the development and commercialization of advanced therapies. Regulatory bodies are providing clear guidelines which helps developers navigate the complex approval process more efficiently. This has given a boost of confidence to investors and accelerated clinical research. Streamlined regulations have also helped address delays and uncertainties that were previously deterring companies from entering this lucrative market. As regulations continue to evolve, the Middle East and Asia Pacific cell and gene therapy market is well positioned to capture significant opportunities in the coming years.
Segment Analysis
The Middle East and Asia Pacific cell and gene therapy market is dominated by the stem cell therapy sub segment. Stem cell therapy is widely used for treating conditions such as cancer, bone and cartilage damage, blood disorders, diabetes, heart disease, and neurological disorders. It is expected to grow at a high rate over the forecast period owing to increasing R&D activities focusing on developing more effective stem cell therapies for various diseases.
Key Takeaways
The Middle East And Asia Pacific Cell And Gene Therapy Market Demand is expected to witness high growth over the forecast period of 2024 to 2031. The global Middle East and Asia Pacific Cell and Gene Therapy Market is estimated to be valued at US$ 4147.82 Th in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024 to 2031.
Regional analysis
The Asia Pacific region currently dominates the Middle East and Asia Pacific cell and gene therapy market with over 40% share and is expected to continue its dominance over the forecast period. Countries such as China, Japan, and India have been leading the adoption of advanced cell and gene therapies owing to presence of large patient pools, rising medical tourism, and improving regulatory guidelines supporting clinical trials. Furthermore, growing collaborations between regional and global market players are also contributing to the rapid market growth.
Key players
Key players operating in the Middle East and Asia Pacific cell and gene therapy market are BASF SE, Croda Health Care, JRS Pharma, Lipoid GmbH, Azelis, U.K. Vet Chem, Gattefoss, Synergy API, Anzchem, and Vantage. These players are focusing on new product launches, collaborations, and geographic expansions to strengthen their market positions. For instance, BASF SE launched a new gene therapy platform to support development and manufacturing of advanced cell and gene therapies.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
